Japan pricing & market access: Launch pricing in the era of US MFN

Published on May 6, 2026

This webinar examines Japan's Pricing & Market Access (P&MA) environment in the context of the US Most Favored Nation (MFN) policy. Drawing on recent policy developments and pricing and reimbursement outcomes for innovative medicines, it will provide insights into Japan’s role in the global pricing landscape and strategies for optimizing launch pricing and market access outcomes.  

Participants will learn:

  • How Japan's drug prices could affect global pricing through international reference pricing (IRP) under MFN
  • How Japan's P&MA environment has responded to MFN, including payer and industry perspectives and recent policy changes
  • Recent pricing and reimbursement outcomes for innovative medicines in Japan and the factors shaping those results
    • …

    Webinar Japan Pricing & Market Access

Continue reading on website
Other news

Driving commercial growth through sales and pricing for an outdoor surfacing provider 

May 5, 2026

EU health policy at a turning point: What pharma needs to know for launch, P&MA, and commercial strategy

May 6, 2026
The EU health policy landscape is shifting fast and the implications for pharma launch planning, pricing and market access (P&MA), and commercial strategy are significant.With EU Pharmaceutical Legislation reform and the Critical Medicines Act taking shape, companies are facing new questions around launch obligations, supply resilience, procurement, and access strategy.Join our upcoming webinar, w